Gantenerumab Lowers Key Protein Levels in Early-onset Disease Trial

The investigational therapy gantenerumab significantly lowered levels of established biomarkers in a rare, inherited form of early-onset Alzheimer’s disease, despite failing to slow cognitive decline or memory loss in symptomatic and asymptomatic patients, according to data from a Phase 2/3 clinical trial. Based on these results, enrolled patients…

Failure of Lilly’s Solanezumab Not Seen as Conclusive Proof That Amyloid Theory Is Flawed

The Alzheimer’s community lamented Eli Lilly’s recent announcement that its experimental therapy solanezumab failed to demonstrate efficacy in treating the disease in recent clinical trials. In the announcement, released Nov. 23, Lilly said it would not pursue regulartory approval for the drug. Solanezumab’s inability to demonstrate effectiveness in people with mild demential due to…

CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher

Two previously failed drug candidates, Eli Lilly’s Solanezumab and Roche’s Gantenerumab, are again under clinical study for Alzheimer’s disease. Both drugs are immunotherapies targeting amyloid-beta in the brain, a target that researchers — including Dr. Michael Geschwind, who spoke with Alzheimer’s News Today — think has the potential to revolutionize…

Eli Lilly & Co. Ends Partnership with UCSD for Asymptomatic Alzheimer’s Disease Study With Solanezumab

Soon-to-be former partners in a promising Alzheimer’s research program, Eli Lilly and Co. and the University of California San Diego (UCSD) have moved a step closer to ending the contract that covers the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study, a groundbreaking clinical trial that aims to test solanezumab. This Phase…